Lonza’s Synaffix Partners with Qurient to Develop Dual-Payload ADC
Synaffix B.V., a Lonza company focused on advancing clinical-stage antibody-drug conjugate (ADC) technologies, has entered into a licensing agreement with South Korea–based…
Read More...
Read More...
